The lowa Oncology Research Association (lORA) is a multidisciplinary consortium of nine lowa hospitals, eighteen gynecologic, medical, pediatric, radiation, and surgical oncology practices and 72 physicians. In addition to the operations office in Des Moines, the lORA has four affiliate sites located in Ames, Council Bluffs, Mason City and Ottumwa and a pediatric component located at the Blank Children's Hospital in Des Moines. The lORA has been a principal member of the North Central Cancer Treatment Group (NCCTG) since 1979 and has secondary research base relationships with the Eastern Cooperative Oncology Group (ECOG), National Surgical Adjuvant Breast and Bowel Project (NSABP), Gynecologic Oncology Group (GOG), Comprehensive Cancer Center Wake Forest University (CCCWFU), and the Children's Oncology Group (COG). The lORA also actively participates in other non-member research base studies through the Cancer Trials Support Unit (CTSU). The goals of lORA are: 1) Provide excellence in cancer care to patients and families through participation in high quality cancer research;2) Support the goals and work of research bases with involvement of lORA investigators, research staff, and patient populations;3) Increase public and professional awareness of clinical trials through community outreach efforts and collaboration with other medical providers in the community;4) Increase accrual in cancer control studies by building on prior recruitment strategies implemented in previous cancer control/cancer prevention studies;5) Develop strategies to increase clinical trial participation i minority groups and the underserved population in rural areas;6) Collaborate with local health care institutions to increase participation in correlative and translational biospecimen studies.
The lORA has a proven track record as an efficient and disciplined team from five strategically located lowa communities. The organization is the link between clinical trials and a significant portion of the state of lowa with a catchment area that includes 59 counties and 50% of the state's population. The lORA will continue to enthusiastically emphasize quality in its research efforts and collaborate with local resources to promote clinical trial participation.
|Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85|
|Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703|
|Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55|
|Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:|
|Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068|
|Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26|
|Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32|
|Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9|
|Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76|
|Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83|
Showing the most recent 10 out of 160 publications